Screener
GeneDx Holdings WGS Self-pay patients — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by GeneDx Holdings in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: GeneDx Holdings’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001818331-26-000041
| Line item | Three months ended March 31, 2026 / Gene Dx | Three months ended March 31, 2026 / Other(1) | Three months ended March 31, 2026 / Total | Three months ended March 31, 2025 / Gene Dx | Three months ended March 31, 2025 / Other(1) | Three months ended March 31, 2025 / Total |
|---|---|---|---|---|---|---|
| Diagnostic test revenue: | ||||||
| Patients with third-party insurance | $84,919 | — | $84,919 | $68,059 | — | $68,059 |
| Institutional customers | 15,528 | 566 | 16,094 | 17,604 | — | 17,604 |
| Self-pay patients | 286 | — | 286 | 96 | — | 96 |
| Total diagnostic test revenue | 100,733 | 566 | 101,299 | 85,759 | — | 85,759 |
| Other revenue | 763 | 192 | 955 | 1,356 | — | 1,356 |
| Total | $101,496 | $758 | $102,254 | $87,115 | — | $87,115 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is GeneDx Holdings's self-pay patients — total revenue?
- GeneDx Holdings (WGS) reported self-pay patients — total revenue of $286K in Q1 2026.
- How has GeneDx Holdings's self-pay patients — total revenue changed year-over-year?
- GeneDx Holdings's self-pay patients — total revenue increased by 197.9% year-over-year, from $96K to $286K.
- What is the long-term trend for GeneDx Holdings's self-pay patients — total revenue?
- Over 4 years (2021 to 2025), GeneDx Holdings's self-pay patients — total revenue has grown at a -23.9% compound annual growth rate (CAGR), from $4.06M to $1.36M.
- What does self-pay patients — total revenue mean?
- This metric represents the total gross revenue generated from diagnostic testing services provided to patients who pay directly for services rather than through third-party insurance providers. It serves as a key indicator of the company's ability to capture market share in the direct-to-consumer or uninsured patient segments. Monitoring this revenue stream helps assess the demand for specialized diagnostic offerings outside of traditional reimbursement channels.
Ask your AI about GeneDx Holdings's self-pay patients — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude